Propranolol Decreases the Viability and Triggers Apoptosis in Hemangioblastoma Cells from Von Hippel-Lindau PatientsVirginia Albinana1, Karina Villar Gómez de las Heras2, Mercedes Mota-Perez2 and Luisa María Botella1,3*
- *Corresponding Author:
Luisa María Botella
Centro de Investigaciones Biológicas
Biomédica en Red de Enfermedades Raras (CIBERER)
E-mail: [email protected]
Received: October 20, 2015 Accepted: January 21, 2016 Published: January 29, 2016
Citation: Albinana V, Villar K, Mota-Perez M, Botella LM (2016) Propranolol Decreases the Viability and Triggers Apoptosis in Hemangioblastoma Cells from Von Hippel-Lindau Patients. J Mult Scler (Foster City) 3:166. doi:10.4172/2376-0389.1000166
Copyright: © 2016 Albinana V, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
In our previous paper, propranolol is used in hemangioblastomas primary cultures from patients with von Hippel- Lindau disease. This is a rare inherited oncologic condition characterized by the growth of tumors affecting mainly the central nervous system, but also kidneys, pancreas, adrenal glands, retinas and endolymphatic sacs (inner ear). Up to date, the only treatment for these patients is surgery. The search for drugs able, at least, to stop the development of hemangioblastomas, has led our group to propose propranolol, a non-specific beta blocker, as a drug to test. According to the results of this work, propranolol would act by decreasing hypoxia signaling pathway, which is constitutively active in VHL patients, normalizing the hypoxia target genes involved in angiogenesis, survival and stemness in the hemangioblastoma cells. The results in vitro are promising and, in the absence of serious side effects, propranolol could be assayed as a therapy in the clinical practice for VHL patients.